Cytokinetics Q2 Loss Narrows More Than Expected, But Underlying Burn Mounts

What happened

Cytokinetics posted a Q2 2026 loss of $1.50 per share, beating consensus of a $1.63 loss, while revenue exceeded estimates, marking the first full quarter with Myqorzo commercial sales following its January 2026 launch. The narrower loss is a relative bright spot, but it still represents a clear widening from the $1.12 loss a year ago as the company ramps up its specialty cardiology sales force and R&D investments. Early revenue traction likely reflects initial Myqorzo prescriptions, yet against a ~$7.7 billion market cap and a balance sheet carrying negative equity and high fixed royalty claims, it does little to dent the aggressive market-share assumptions embedded in the stock. With Camzyos already entrenched and the ACACIA nHCM readout still months away, even modestly better early numbers leave the risk-reward skewed to the downside from a crowded bullish position. Today’s report keeps the launch narrative alive but does not alter the core concern that valuation discounts flawless execution in a fiercely competitive market.

Implication

While better-than-expected Q2 revenue suggests Myqorzo may be gaining early traction, the widening loss and strained balance sheet keep risk elevated, and until we see durable commercial trends and positive ACACIA nHCM data, the stock remains a 'show-me' story where upside is limited and downside looms if growth stalls.

Thesis delta

The Q2 earnings beat incrementally supports the Myqorzo launch thesis, but the loss widened year-over-year and the competitive landscape remains challenging. Consequently, the deep value report's potential sell rating is unchanged, as the stock still discounts aggressive growth that must be executed flawlessly.